Mutational Damages in Malignant Lung Tumors

Document Type : Research Articles

Authors

1 Chair of Molecular Biology with Courses in Chemistry and Biochemistry, Kazakhstan-Russian Medical University, Almaty, Republic of Kazakhstan.

2 Molecular Genetic Research Center, Kazakh Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan.

3 Department of Scientific Management and Grant Research, Kazakh Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan.

4 Department of Chemical and Biochemical Engineering, Institute of Chemical and Biological Sciences, Satbayev University, Almaty, Republic of Kazakhstan.

5 Department of Research and Strategic Development, Kazakh Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan.

Abstract

Background: Today, genomic changes are an important cause of the occurrence, growth and progression of cancer. Technological advances in cancer genomic analysis platforms have made it possible to identify genomic alterations that may influence response to lung cancer treatment. Methods: The study examined tumor growth-inhibiting oncogenes and genes responsible for cell growth and division to identify mutations characteristic of malignant lung tumors. The mutations were studied in 400 postoperative samples after amplifying p53 and HRAS fragments and p53, p21Waf1, MDM2 mRNA. p53 or p21Waf1 were expressed in 50% of squamous cell carcinomas and adenocarcinomas of the lung. Results: The study examined tumor growth-inhibiting oncogenes and genes responsible for cell growth and division to identify mutations characteristic of malignant lung tumors. The mutations were studied in 400 postoperative samples after amplifying p53 and HRAS fragments and p53, p21Waf1, MDM2 mRNA. p53 or p21Waf1 were expressed in 50% of squamous cell carcinomas and adenocarcinomas of the lung. HRAS mutations were present in most squamous cell carcinomas and adenocarcinomas of the lung. EcoR1- and Pst1- restriction enzymes destroyed the RT-PCR product of the p53 and p21Waf1 mRNA and increased the level of detected mutations in lung adenocarcinoma to 75% and 50 %, respectively. EGFR mutations were more frequent in lung adenocarcinoma than in lung squamous cell carcinoma. Mutations in EGFR exons 19 and 21 found in 65 of 263 lung tumor samples indicated the tumor sensitivity to EGFR tyrosine kinase inhibitors. EGFR deletions in exon 19 occurred mainly in adenocarcinoma, L858R mutations in EGFR exon 21 were quite common in lung adenocarcinoma. Conclusion: The mutations detected in most squamous cell carcinomas and adenocarcinomas of the lung could be used to diagnose and predict the disease severity and targeted therapy efficacy.

Keywords

Main Subjects

Asian Pacific Journal of Cancer Prevention
Volume 24, Issue 2
February 2023
Pages 709-716

Files

History

  • Receive Date: 28 October 2022
  • Revise Date: 23 December 2022
  • Accept Date: 18 February 2023

Share

How to cite

Statistics